Abstract
This study examined the effects of glutamate receptor agonists on the release of neuropeptide FF-like immunoreactivity from rat spinal dorsal half slices. Glutamate (10 μM) only induced release in Mg 2+-free medium enriched with glycine (1 μM) and with slight depolarization (15 mM K +). This effect was abolished by the NMDA receptor antagonist, 2-amino-5-phosphonovalerate (100 μM), suggesting major participation of NMDA receptors. The quisqualate and metabotropic receptor agonists, α-amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) and trans-1-hydroxy-5-methylisoxazole-4-propionate ( t-ACPD) respectively, had no effect at 10 μM. In contrast, NMDA dose dependently stimulated neuropeptide FF release, even in the presence of the Na + channel blocker, tetrodotoxin (1 μM), suggesting that NMDA receptors involved in the release of neuropeptide FF are mainly located on nerve terminals. The NMDA receptor antagonists, 2-amino-5-phosphonovalerate or (+)-5- methyl-10−11- dihydro-5 H-dibenzo [ a, d]cyclohepten-5,10-imine (MK-801) (100 μM), blocked the 10 μM NMDA effect. Furthermore, neuropeptide FF-like material inhibited binding of [ 125I]Y8Fa, a radioiodinated analog of neuropeptide FF, to spinal membranes, suggesting physiological relevance of NMDA-induced release. Taken together, these results suggest a relationship between neuropeptide FF and NMDA receptors in the spinal cord.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.